Q1 Earnings Forecast for Prenetics Global Issued By Sidoti

Prenetics Global Limited (NASDAQ:PRE) – Investment analysts at Sidoti raised their Q1 2028 earnings per share estimates for shares of Prenetics Global in a research note issued on Wednesday, August 19th. Sidoti analyst A. Hantman now anticipates that the company will post earnings of $0.29 per share for the quarter, up from their prior estimate of $0.28. The consensus estimate for Prenetics Global’s current full-year earnings is ($1.28) per share. Sidoti also issued estimates for Prenetics Global’s FY2028 earnings at $2.12 EPS.

Prenetics Global (NASDAQ:PRE) last posted its earnings results on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.11. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 19.46%. The firm had revenue of $46.49 million during the quarter, compared to the consensus estimate of $49.02 million.

PRE has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a research note on Friday, July 17th. Benchmark upped their price target on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, Wall Street Zen downgraded Prenetics Global from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.25.

Prenetics Global Stock Down 3.3%

Shares of PRE stock opened at $18.76 on Thursday. Prenetics Global has a fifty-two week low of $7.18 and a fifty-two week high of $23.63. The firm’s 50 day moving average price is $19.13 and its two-hundred day moving average price is $18.88. The stock has a market cap of $316.48 million, a price-to-earnings ratio of -4.51 and a beta of 0.26.

Institutional Trading of Prenetics Global

Large investors have recently bought and sold shares of the company. Wells Fargo & Company MN purchased a new stake in shares of Prenetics Global during the fourth quarter valued at approximately $47,000. State of Wyoming purchased a new position in shares of Prenetics Global in the first quarter valued at $48,000. JPMorgan Chase & Co. acquired a new stake in Prenetics Global during the 3rd quarter valued at $65,000. Manatuck Hill Partners LLC acquired a new stake in Prenetics Global during the 4th quarter valued at $170,000. Finally, T3 Companies LLC purchased a new stake in Prenetics Global during the 4th quarter worth $170,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.